LH · Labcorp Holdings Inc
Price
Snapshot
50 fields · last close| Market Cap | $26.88B |
| P/E | 26.91 |
| Float | 80.56M |
| Beta | 0.88 |
| Volatility | 22.1% |
| Exchange | NYSE |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 84 |
| Price | 327.83 |
| Change | −1.11% |
| Prev Close | 331.50 |
| Open | 333.47 |
| Day Low | 329.38 |
| Day High | 335.74 |
| Avg Vol | 1 |
| Avg $ Vol | $218.3M |
| 52W High | 341.80 |
| 52W Low | 244.52 |
| 52W Pos | 85.6% |
| From High | −4.09% |
| From Low | +34.07% |
| Max DD 1Y | −15.22% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.36% |
| SMA 50 | +7.37% |
| SMA 200 | +19.11% |
| RSI (14) | 61.6 |
| Vol 30D | 22.6% |
| Vol 90D | 22.1% |
| 1Y Range | 245–342 |
| Daily bars | 506 |
| Perf Week | −1.50% |
| Perf Month | +5.59% |
| Perf Quarter | +27.03% |
| Perf Half Y | +20.14% |
| Perf Year | +21.06% |
| Perf YTD | +30.27% |
| Prev Day | −1.11% |
| Clavix | A- |
| Debt / Eq | 0.66 |
| Curr Ratio | 1.42 |
| Int Cover | 6.2× |
| FCF Margin | 8.5% |
| Rev Growth | +5.8% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 3 / 47 |
What LH does
Labcorp Holdings Inc. provides laboratory services.
It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests.
It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations.
In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI‑enabled Test Selection, a generative AI‑enabled tool.
It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs.
The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics.
It also has a collaboration with Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer.
The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Clavix risk grade
regraded every trading dayLH grades A-, 84 of 100. Steadiest on Price Stability (69), most exposed on News Sentiment (67, steady). 3 of the 4 weighted dimensions sit above the Health Care median. Ranks 3 of 47 in Health Care by Clavix score.
How rough the ride is
| LH | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.88 | 0.81 |
| Volatilityannualized | 22.1% | 20.4% |
| Max drawdown, past yearworst peak-to-trough fall | −15.2% | — |
| Typical daily movemedian absolute daily change | 0.83% | — |
| Days beyond ±3%of the last 252 sessions | 114% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| LH | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.88 | 0.81 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate55% of 47 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| LH | |
|---|---|
| 1 week | −1.5% |
| 1 month | +5.6% |
| Year to date | +30.3% |
| 1 year | +21.1% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| LH | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 27 Jul |
| Average score0 most bearish, 100 most bullish | 67 |
| Bullish · bearisharticles above 60 · below 40 | 22 · 3 |
| Directionarticles whose tone is improving vs worsening | 22 ↑ 3 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 47 Health Care names Clavix covers; the tick is the sector median.
Growth
| LH | |
|---|---|
| Revenue growthyear over year | +5.8% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Health Care
47 companies| Metric | LH | Sector spread | Median |
|---|---|---|---|
| Beta | 0.88 | 0.81 | |
| Volatility | 22.1% | 20.4% | |
| P/E | 26.91 | 26.14 | |
| Debt / equity | 0.66 | 0.71 | |
| Current ratio | 1.42 | 1.58 | |
| FCF margin | 8.5% | 8.6% | |
| Interest coverage | 6.2× | 6.3× |
Recent news
most recent scored articles · the chip is the article’s score · click to openLabcorp announced an upgraded digital experience for Labcorp Global Trial Connect™, its portfolio of clinical trial services, data and technology, aimed at improving visibility, simplifying workflows, and supporting faster decision-making for sponsors and investigator sites.
Labcorp has launched a new reflex testing solution for hepatitis D, aimed at helping doctors identify patients with this rarer but more severe form of the virus earlier. The test is designed to fill a gap in monitoring for the disease.
An analysis of Labcorp (LH) weighs the company's specialty-testing expansion, strategic partnerships, and share buybacks as reasons to hold the stock, against reimbursement pressure and cost pressure as risks.
No specific new development, financial result, or event is reported in the body text.
Labcorp announced it will offer the Elecsys pTau-217 blood test after it received FDA clearance. The test measures a blood protein (pTau-217) linked to amyloid buildup in the brain, a hallmark of Alzheimer's disease, and is designed to help doctors rule the condition in or out for patients aged 55 and older showing signs of cognitive decline.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| DGX | Quest Diagnostics Inc | A- | $26.42B | 24.97 | 0.56 | Compare |
| ALC | Alcon AG | B+ | $29.66B | 44.75 | 1.12 | Compare |
| GEHC | GE Healthcare Technologies Inc | B- | $31.49B | 16.79 | 0.82 | Compare |
| STE | STERIS plc | A- | $22.12B | 27.69 | 0.88 | Compare |
| RMD | Resmed Inc | B+ | $33.06B | 21.74 | 0.77 | Compare |
| GH | Guardant Health Inc | C+ | $21.61B | — | 1.73 | Compare |
| CNC | Centene Corp | B | $33.60B | — | 1.08 | Compare |
| DXCM | Dexcom Inc | B | $33.85B | 33.86 | 1.45 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.